148.85k followers • 21 symbols Watchlist by Yahoo Finance
Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis
Curated by Yahoo Finance
Global spending on legal cannabis worldwide will hit $57 billion in a decade, according to Arcview Market Research and BDS Analytics. Driven by the legalization of recreational and medical cannabis and the increasing demand for both, legal cannabis revenue in the U.S. is projected to hit $23.4 billion by 2022. Yahoo Finance is now tracking the major players in the cannabis industry.How do we pick these stocks?
This is a curated list, powered by Yahoo Finance’s algorithm and intelligence from our millions of users as well as the Yahoo Finance editorial team. The list covers companies in horticulture, pharmaceutical research and ancillary businesses. We will continue to add names as corporations invest and pivot into the space.How are these weighted?
The stocks on this watchlist are weighted equally at the time they were added.
To learn what every company on this list is doing that involves cannabis, read this story.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|ABBV||AbbVie Inc.||117.21||+0.32||+0.27%||4:04 pm GMT-4||8.04M||6.94M||207.02B|
|BUD||Anheuser-Busch InBev SA/NV||74.75||-0.59||-0.78%||4:00 pm GMT-4||616.50k||1.47M||147.28B|
|MO||Altria Group, Inc.||49.99||-0.22||-0.44%||4:02 pm GMT-4||5.16M||10.64M||92.51B|
|SMG||The Scotts Miracle-Gro Company||223.11||-5.92||-2.58%||4:00 pm GMT-4||364.98k||386.80k||12.43B|
|TAP||Molson Coors Beverage Company||55.48||-2.45||-4.23%||4:04 pm GMT-4||2.93M||2.40M||12.03B|
|WEED.TO||Canopy Growth Corporation||28.22||+0.28||+1.00%||3:59 pm GMT-4||764.09k||1.12M||10.79B|
|CGC||Canopy Growth Corporation||23.4||+0.25||+1.08%||4:00 pm GMT-4||2.06M||3.60M||8.91B|
|TLRY||Tilray, Inc.||15.58||+0.42||+2.77%||4:00 pm GMT-4||18.73M||22.95M||6.95B|
|GWPH||GW Pharmaceuticals plc||218.96||-||-||4:00 pm GMT-4||1.46M||705.36k||6.81B|
|CRON||Cronos Group Inc.||7.53||+0.10||+1.35%||4:00 pm GMT-4||1.58M||3.15M||2.79B|
|ACB||Aurora Cannabis Inc.||7.38||+0.36||+5.13%||4:00 pm GMT-4||5.33M||9.34M||1.46B|
|NBEV||NewAge, Inc.||2.1||+0.03||+1.45%||4:00 pm GMT-4||1.72M||2.03M||284.49M|
|CRBP||Corbus Pharmaceuticals Holdings, Inc.||1.63||+0.04||+2.52%||4:00 pm GMT-4||1.99M||5.12M||203.80M|
|TGOD.TO||The Green Organic Dutchman Holdings Ltd.||0.315||+0.02||+6.78%||3:59 pm GMT-4||793.94k||1.87M||166.07M|
|TGODF||The Green Organic Dutchman Holdings Ltd.||0.2616||+0.01||+5.23%||3:52 pm GMT-4||347.89k||1.19M||135.08M|
|TRTC||Terra Tech Corp.||0.23||-0.00||-2.04%||3:57 pm GMT-4||1.14M||1.22M||53.30M|
|CANN||General Cannabis Corp||0.692||+0.00||+0.29%||3:46 pm GMT-4||52.46k||207.07k||43.01M|
|MJ||ETFMG Alternative Harvest ETF||20.32||+0.40||+2.01%||4:00 pm GMT-4||1.15M||1.58M||-|
AbbVie Inc (NYSE: ABBV) significantly inflated prices over the past two decades for patients in the U.S. who take the drugs Humira and Imbruvica, a report released by the House Oversight and Reform Committee found. The committee concluded that the price increases led to billions of dollars in corporate revenue and hefty bonuses for company executives. “AbbVie pursued a variety of tactics to increase drug sales while raising prices for Americans, including exploiting the patent system to extend its market monopoly, abusing orphan drug protections to further block competition, and engaging in anticompetitive pricing practices,” the report states. The report comes after the panel reviewed more than 170,000 internal data, documents, and communications related to the medications over the last 18 years. Chairwoman Carolyn Maloney, D-N.Y., issued a subpoena for the documents last year because the company refused to cooperate with a previous request for the materials. A representative for AbbVie did not respond to a request for comment. Humira, a rheumatoid arthritis treatment, was released in 2003 when the company was Abbott Laboratories. AbbVie has since raised the cost frequently, and by more than 470%, with an annual supply now costing about $77,000, the report said. In 2020 alone, AbbVie reported billion in U.S. net revenue for Humira. AbbVie faces no current competition in the U.S. from biosimilar versions of Humira, even though six biosimilars have received FDA approval. Meanwhile, AbbVie, in conjunction with Janssen Biotech, has increased the price of Imbruvica, a drug used to treat mantle cell lymphoma and other cancers, by 82% since it launched in 2013. In 2013, the drug was priced at $99,776 annually. Today, it’s priced at $181,529. Experts estimate that by 2026, Imbruvica will be the fourth best-selling drug in the U.S. Today’s full committee hybrid hearing with AbbVie CEO Richard Gonzalez and experts on pricing practices for Humira and Imbruvica has begun at 10:00 a.m. ET. Price Action: ABBV shares closed up 0.27% at $117.21 on Tuesday. See more from BenzingaClick here for options trades from BenzingaSoliton Stock Rallies After .60/Share Buyout From AbbVie© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
AbbVie’s pricing practices for some of its top-selling medicines faced fresh scrutiny from federal lawmakers Tuesday, the latest effort by members of Congress probing the cost of prescription drugs.
Tilray shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 69 to 81.